Janux Therapeutics JANX
$10.08 −$0.21 (-2.04%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $10.15 +0.69%
Open$10.11
Prev close$10.29
Day range$10.05 – $10.54
Volume1.11M
Market cap$616.73M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$9.29M-7.1% YoY
Operating profit-$31.26M+11.3% YoY
Net profit-$21.57M+11.3% YoY
Diluted EPS-$0.34+12.8% YoY
Free cash flow-$25.18M-94.5% YoY
Operating cash flow-$25.18M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-599.3%
Net margin-428.7%
Return on equity-10.6%
Return on assets-9.9%
Return on invested capital-14.5%
Current ratio17.69
Liabilities / assets7.3%
Cash & investments$945.72M
Total debt$17.75M
Net cash (debt)$927.97M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $9.29M | $10.27M | $3.73M | $10.00M | $0.00 |
| Total Operating Revenue | $9.29M | $10.27M | $3.73M | $10.00M | $0.00 |
| Operating Expense | $40.55M | $41.96M | $37.95M | $167.67M | $42.40M |
| Selling and Admin Expenses | $9.98M | $10.96M | $11.13M | $41.77M | $10.85M |
| -General & Admin Expense | $9.98M | $10.96M | $11.13M | $41.77M | $10.85M |
| Research & Development | $30.57M | $30.99M | $26.81M | $125.90M | $31.55M |
| Operating Profit | -$31.26M | -$31.69M | -$34.21M | -$157.67M | -$42.40M |
| Net Non-Operating Interest Income (Expense) | $9.69M | $9.72M | $9.85M | $44.04M | $10.46M |
| Non-Operating Interest Income | $9.69M | $9.72M | $9.85M | $44.04M | $10.46M |
| Pretax Profit | -$21.57M | -$21.97M | -$24.36M | -$113.63M | -$31.95M |
| Net Profit | -$21.57M | -$21.97M | -$24.36M | -$113.63M | -$31.95M |
| Profit from Continuing Operations | -$21.57M | -$21.97M | -$24.36M | -$113.63M | -$31.95M |
| Net Income to Parent Company | -$21.57M | -$21.97M | -$24.36M | -$113.63M | -$31.95M |
| Net Income to Common Stockholders | -$21.57M | -$21.97M | -$24.36M | -$113.63M | -$31.95M |
| Basic EPS | -$0.34 | -$0.35 | -$0.39 | -$1.83 | -$0.51 |
| Diluted EPS | -$0.34 | -$0.35 | -$0.39 | -$1.83 | -$0.51 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $983.66M | $1.01B | $1.03B | $1.00B | $1.00B |
| Total Current Assets | $959.38M | $983.34M | $1.00B | $975.89M | $975.89M |
| Cash and Cash Equivalents & Short-Term Investments | $945.72M | $970.91M | $956.39M | $966.57M | $966.57M |
| -Cash and Cash Equivalents | $41.82M | $27.77M | $51.83M | $52.33M | $52.33M |
| -Short Term Investments | $903.90M | $943.15M | $904.56M | $914.23M | $914.23M |
| Receivables | $6.61M | $6.33M | $42.46M | $6.43M | $6.43M |
| -Accounts Receivable | $411,000.00 | $149,000.00 | $35.00M | – | – |
| -Accrued Interest Receivable | $6.20M | $6.18M | $7.46M | $6.43M | $6.43M |
| Prepaid Assets | $7.05M | $6.10M | $3.20M | $2.89M | $2.89M |
| Total Non-Current Assets | $24.27M | $24.32M | $26.18M | $25.68M | $25.68M |
| Net PPE | $19.57M | $20.59M | $21.42M | $22.25M | $22.25M |
| -Gross PPE | $27.79M | $28.40M | $28.77M | $29.22M | $29.22M |
| -Accumulated Depreciation | -$8.22M | -$7.82M | -$7.35M | -$6.97M | -$6.97M |
| Other Non-Current Assets | $4.71M | $3.73M | $4.76M | $3.42M | $3.42M |
| Total Liabilities | $72.04M | $79.67M | $86.69M | $44.74M | $44.74M |
| Total Current Liabilities | $54.25M | $60.15M | $58.92M | $25.00M | $25.00M |
| Payables | $4.30M | $3.02M | $3.38M | $4.97M | $4.97M |
| -Accounts Payable | $4.30M | $3.02M | $3.38M | $4.97M | $4.97M |
| Current Accrued Expenses | $15.90M | $16.41M | $13.23M | $13.04M | $13.04M |
| Short-Term Debt and Capital Lease Obligation | $2.63M | $2.55M | $2.47M | $2.39M | $2.39M |
| -Current Capital Lease Obligation | $2.63M | $2.55M | $2.47M | $2.39M | $2.39M |
| Current Deferred Liabilities | $27.22M | $35.07M | $37.59M | – | – |
| Total Non-Current Liabilities | $17.80M | $19.52M | $27.78M | $19.75M | $19.75M |
| Long Term Debt and Capital Lease Obligation | $17.75M | $18.44M | $19.10M | $19.75M | $19.75M |
| -Long Term Capital Lease Obligation | $17.75M | $18.44M | $19.10M | $19.75M | $19.75M |
| Non-Current Deferred Liabilities | $50,000.00 | $1.08M | $8.68M | – | – |
| Total Equity | $911.61M | $927.98M | $941.54M | $956.82M | $956.82M |
| Stockholders' Equity | $911.61M | $927.98M | $941.54M | $956.82M | $956.82M |
| Capital Stock | $61,000.00 | $61,000.00 | $60,000.00 | $60,000.00 | $60,000.00 |
| -Common Stock | $61,000.00 | $61,000.00 | $60,000.00 | $60,000.00 | $60,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.34B | $1.33B | $1.32B | $1.30B | $1.30B |
| Retained Earnings | -$419.29M | -$397.72M | -$375.74M | -$351.38M | -$351.38M |
| Gains/Losses Not Affecting Retained Earnings | -$6.49M | -$2.31M | $576,000.00 | $4.32M | $4.32M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$25.18M | $12.48M | -$12.34M | -$82.24M | -$28.54M |
| Net cash flow from continuing operations | -$25.18M | $12.48M | -$12.34M | -$82.24M | -$28.54M |
| Net Income from Continuing Operations | -$21.57M | -$21.97M | -$24.36M | -$113.63M | -$31.95M |
| Depreciation & Depletion & Amortization | $458,000.00 | $463,000.00 | $469,000.00 | $2.03M | $468,000.00 |
| Change in Working Capital | -$9.28M | $27.82M | $4.91M | $6.71M | -$3.06M |
| -Change in Receivables | -$262,000.00 | $34.85M | -$35.00M | – | – |
| -Change in Prepaid Assets | -$979,000.00 | -$1.61M | -$1.34M | -$827,000.00 | -$227,000.00 |
| -Change in Payables and Accrued Expense | $1.87M | $3.70M | -$3.64M | $7.27M | -$2.85M |
| -Change in Other Current Assets | -$977,000.00 | $1.03M | -$1.34M | $276,000.00 | $19,000.00 |
| -Change In Other Working Capital | -$8.93M | -$10.16M | $46.23M | -$2,000.00 | $0.00 |
| Net cash flow from investing | $38.38M | -$38.78M | $8.29M | -$300.98M | $29.54M |
| Net Cash Flow from Continuing Investing Activities | $38.38M | -$38.78M | $8.29M | -$300.98M | $29.54M |
| Net PPE Purchase and Sale | -$2,000.00 | -$202,000.00 | -$273,000.00 | -$1.04M | -$106,000.00 |
| Net Investment Purchase and Sale | $38.38M | -$38.58M | $8.56M | -$299.94M | $29.65M |
| Financing Cash Flow | $852,000.00 | $2.24M | $3.55M | $4.95M | $2.94M |
| Net Cash Flow from Continuing Financing Activities | $852,000.00 | $2.24M | $3.55M | $4.95M | $2.94M |
| Net Common Stock Issuance | $0.00 | $0.00 | $0.00 | -$347,000.00 | $0.00 |
| Proceeds from Stock Option Exercised | $852,000.00 | $2.24M | $3.55M | $5.29M | $2.94M |
| Ending Cash Balance | $42.63M | $28.58M | $52.64M | $53.15M | $53.15M |
| Net Change in Cash | $14.05M | -$24.06M | -$506,000.00 | -$378.27M | $3.95M |
| Beginning Cash Balance | $28.58M | $52.64M | $53.15M | $431.42M | $49.21M |
| Free Cash Flow | -$25.18M | $12.28M | -$12.61M | -$83.28M | -$28.65M |
No comments yet — be the first to weigh in on JANX.
Sign in to join the discussion.